NCT07870122Not yet recruiting
Sleep Quality, Adiposity and Diet Quality
Association of Sleep Quality With Visceral Adiposity, Cardiovascular Disease Risk, and Diet Quality in Individuals With Type 2 Diabetes
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
The aim of this study is to evaluate the effects of sleep quality on cardiovascular disease risk and food and nutrient intakes. Within the scope of this study, several parameters associated with cardiovascular disease risk will be assessed, including waist circumference, hip circumference, waist-to-hip ratio, waist-to-height ratio, triceps skinfold thickness, mid-upper arm circumference, and serum levels of glucose, HbA1c, insulin, LDL cholesterol, HDL cholesterol, total cholesterol, homocysteine, and lipoprotein(a). Cardiovascular disease risk will be evaluated using the Framingham Risk Score, SCORE2, and A Body Shape Index (ABSI). To assess visceral adiposity, a formula incorporating waist circumference and serum triglyceride and HDL cholesterol levels will be used. In addition, participants' body fat and muscle percentages will be determined. Carbohydrate, fat, protein, vitamin, mineral, and fluid intakes will also be compared between individuals with poor and good sleep quality, and the effects of sleep quality on nutrient intake will be evaluated. Previous studies investigating the effects of sleep quality on diabetes or cardiovascular diseases have predominantly been conducted among middle-aged adults aged 50 years and older, a population with a higher prevalence of dysglycemia, dyslipidemia, and hypertension. In the present project, all eligible adults aged 18 years and older will be evaluated. Furthermore, to our knowledge, no previous study has comprehensively evaluated the effects of sleep quality on cardiovascular disease risk together with nutrient intakes among individuals with type 2 diabetes. This study is expected to contribute to the literature by evaluating the effects of sleep quality on cardiovascular disease risk among individuals with type 2 diabetes. In addition, the extent to which sleep quality is associated with dietary habits will be examined at the level of nutrient intake. The findings of this study may provide a basis for educational interventions aimed at emphasizing the importance of sleep quality and improving sleep quality, as well as for future public health initiatives. Improving sleep quality may also contribute to strategies aimed at preventing the development of type 2 diabetes and improving the management of its complications.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 209 (estimated)
- First submitted
- 3 Oct 2026
- Start date
- Nov 2026
- Primary completion date
- Nov 2028
- Lead sponsor
- Izmir Democracy University
- Diseases
- Obesity, Type 2 diabetes
- NCT number
- NCT07870122
What you commit to
- Study type: Observational
- Planned participants: 209
- From Nov 2026 to the primary completion date, Nov 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Individuals using sleep medications and/or experiencing severe sleep problems,
- Individuals using medications that may affect metabolism or sleep quality, such as corticosteroids, statins, or antipsychotics,
- Individuals who use sleep medications and/or have severe sleep problems,
Other illness
- Individuals diagnosed with known nephrolithiasis, glomerulonephritis or lupus nephritis, primary nephrotic syndrome, or other diagnosed kidney diseases,
- Individuals with parathyroid disease,
- Individuals with autoimmune diseases,
- Individuals with an acute infection,
- Individuals with chronic obstructive pulmonary disease,
- Individuals with cardiovascular or cerebrovascular disease,
- Individuals with type 1 diabetes mellitus or forms of diabetes other than type 2 diabetes mellitus,
- Individuals with cancer,
- Individuals with any metabolic health disorder,
Other
- Pregnant or lactating women,
- Individuals using any nutrient supplements or other dietary supplements,
- Individuals who are unwilling to participate in the study.
- Individuals who use any nutrient supplements or other dietary supplements,
- Pregnant or breastfeeding women,
- Individuals who are unwilling to participate in the study.
Who the study is looking for
- \-
- Type 2 diabetes mellitus will be diagnosed based on the presence of any of the following criteria:
- Fasting plasma glucose ≥126 mg/dL (7.0 mmol/L)
- Hemoglobin A1c ≥6.5% (48 mmol/mol)
- Random plasma glucose ≥200 mg/dL (11.1 mmol/L) in the presence of classic symptoms of hyperglycemia, such as excessive thirst, frequent urination, and unexplained weight loss
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Izmir City Hospital Coordinator of this site? Confirm its status | Izmir | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.